Praxis Precision Medicines公司Relutrigine治疗广泛性癫痫的Emerald试验预计2026年底完成

美股速递
Mar 31

Praxis Precision Medicines公司近日公布,其研发的Relutrigine针对广泛性癫痫适应症的Emerald临床试验,预计将于2026年底前完成。该试验的进展备受市场关注,其结果将对公司未来发展产生重要影响。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10